KA - Kineta, Inc. Debt to Book Capitalization Ratio

The trajectory of Kineta, Inc. (KA) financial leverage underscores the business's autonomy from macroeconomic fluctuations, rendering the asset defensive. The value of 0.00 reflects the balance of debt metrics. Kineta, Inc. (KA) relies on its unique drug KVA12.1, which possesses significant pricing power. However, the company operates amidst fierce competition for investment and the risk of more effective therapeutic solutions emerging.

KA: kinetabio.com Debt to Net Assets 04/28/2023 - 09/28/2024

Metric breakdowns and analytics for Kineta Inc (KA)

- price and consensus price forecast:

Price Chart Kineta, Inc.|KA - Price Target Chart

- market capitalization data:

Market Value Kineta Corp|KA - Total Enterprise Value

- book capitalization data:

Book Value per Share Kineta|KA - Book Value of Business|Market Cap to Net Assets Ratio kinetabio.com|KA - Company Assets

- debt and liquidity data:

Total Debt to Equity Ratio Kineta, Inc.|KA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Kineta Bio|KA - Company Total Debt Obligations|Debt to Book Capitalization Ratio Kineta Corp

Summary company analytics:Kineta, Inc. (KA)

The metric is calculated as the ratio of total borrowed funds to net asset value, determining the business's degree of dependence on external financing relative to its own equity. For Kineta, Inc. (KA), this balance is critical when developing costly cancer immunotherapy research. A high debt load could limit investments in the scientific foundation. The historical trend of the debt-to-equity ratio reflects the current financial stability of the company.

Who Kineta, Inc. competes with